Not Many Employers Cover GLP-1 Weight Loss Drugs
Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.
The Unexplored Effects of Weight-Loss Drugs on the Brain
Popular weight-loss drugs like Ozempic are used to treat obesity and diabetes. Now, researchers found that these drugs also affect rodent brains in other ways.
FDA says shortage of popular diabetes, weight-loss drugs resolved
The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — has been resolved.
The FDA issued a warning about compounding pharmacies on weight-loss drugs
A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies against skirting regulatory standards to put them on the market now that shortages are waning.
Eli Lilly’s weight-loss and diabetes drugs are no longer in shortage, says FDA
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in expanding manufacturing.
Lilly's weight-loss drug removed from FDA's shortage list
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely piling pressure on firms selling cheaper versions known as compounded drugs.
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
Eli Lilly’s (NYSE:LLY) blockbuster GLP-1 medication, tirzepatide, is no longer in shortage in the U.S., the U.S. Food and Drug Administration (FDA) said on Wednesday. Tirzepatide, currently marketed by Eli Lilly (LLY) as Mounjaro and Zepbound for diabetes and weight loss,
This trust offers an investment cure as weight-loss wonder drugs’ side effects mount
Investors looking to back the next generation of weight-loss drugs, following a warning that the current blockbuster ...
News Medical on MSN2d
GLP-1 drugs protect brain health by improving neurovascular function and reducing inflammation
Research highlights how GLP-1 receptor agonists may improve brain health by targeting the neurovascular unit, linking ...
Pharmaceutical Technology1mon
Glucagon Like Peptide 1 drugs in development, 2024
GlobalData’s report assesses the drugs in the Glucagon Like Peptide 1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.
thorax.bmj9d
Glucagon-like peptide-1 receptor agonists may benefit cardiopulmonary outcomes in patients with COPD
Background Clinical studies have shown that glucagon-like peptide-1 receptor agonists (GLP-1 RA) can have beneficial effects ...
News Medical1mon
GLP-1 receptor agonists show promise in treating substance use disorders
Review: POTENTIAL ROLE OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS IN SUBSTANCE USE DISORDER: A SYSTEMATIC REVIEW OF RANDOMIZED TRIALS. Image Credit: Designua / Shutterstock A systematic ...
National Academies of Sciences%2c Engineering%2c and Medicine3mon
Examining Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists for Central Nervous System Disorders: A Workshop
to examine potential applications of glucagon-like peptide-1 receptor (GLP-1R) agonists in central nervous system disorders, such as dementia, Parkinson’s disease, substance and alcohol use ...